Arabic Arabic English English French French German German
dark

RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn’s

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that the U.S. Patent and Trademark Office has issued two new patents, one covering opaganib for treating Ebola virus disease, with patent protection until 2035, and the other covering RHB-104 for treating bacterial infections, with protection through 2029. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Connect Biopharma Hires General Counsel & Chief Compliance Officer and Appoints a New Board Member

Next Post

LUNGevity Foundation and Partner Hamoui Family Foundation Issue 2022 Request for Applications for RET-Positive Clinical Lung Cancer Research

Related Posts
Total
0
Share